MWNA
ALBO

Marshall Wace North America’s Albireo Pharma Inc ALBO Stock Holding History

Marshall Wace North America’s Portfolio ALBO Stock Details ALBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-37,393
Closed -$1.25M – 1676
2020
Q3 		$1.25M Buy
+37,393
New +$1.09M 0.01% 742
2020
Q1 		– Sell
-3,104
Closed -$79K – 1701
2019
Q4 		$79K Buy
+3,104
New +$62.1K ﹤0.01% 1090
2019
Q3 		– Sell
-39,888
Closed -$1.29M – 1618
2019
Q2 		$1.29M Buy
39,888
+14,544
+57% +$486K 0.01% 679
2019
Q1 		$816K Buy
+25,344
New +$682K 0.01% 704
2018
Q4 		– Sell
-34,271
Closed -$1.13M – 1698
2018
Q3 		$1.13M Buy
+34,271
New +$1.12M 0.01% 589

Other funds holding ALBO

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Marshall Wace North America's ALBO Position: Q4 2020 in Review

Marshall Wace North America sold out of Albireo Pharma Inc (ALBO) in Q4 2020, closing a stake of 37,393 shares — an estimated $1.25M sold.

Marshall Wace North America first reported a position in ALBO in Q3 2018 and held it in 5 quarters. The position peaked at $1.29M in Q2 2019. 107 funds tracked by Wall St. Rank hold ALBO as of Q4 2020.

  • Marshall Wace North America reported no remaining Albireo Pharma Inc position as of Q4 2020 after selling out during the quarter.
  • Marshall Wace North America sold 37,393 Albireo Pharma Inc shares in Q4 2020, an estimated $1.25M.
  • Marshall Wace North America first reported a position in Albireo Pharma Inc in Q3 2018 and held it in 5 quarters.
  • Marshall Wace North America's Albireo Pharma Inc position peaked at $1.29M in Q2 2019.
  • 107 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q4 2020.

Based on Marshall Wace North America's 13F filing for Q4 2020, filed 16 Feb 2021.